顺铂联合斯奇康胸腔内注入治疗恶性胸腔积液28例  

Clinical Observation of Malignant P leural Effusion Using Cisplatine and Siqikang Intrapleurally Injection

作　　者：兰箭[1] 张和生[1] 

机构地区：[1]重庆医科大学附属第二医院,重庆400010

出　　处：《中国药业》2004年第8期65-66,共2页China Pharmaceuticals

摘　　要：目的:探讨胸腔内注入顺铂和斯奇康治疗恶性胸腔积液的疗效。方法:经病理细胞学证实为肺癌胸膜转移的恶性胸腔积液56例,经胸腔插管引流术排尽胸液后,随机分成两组,治疗组(28例)胸腔内注入顺铂40mg/m2和斯奇康6mg,对照组(28例)仅用顺铂,不用斯奇康,1周后重复1次,最多3次。观察疗效、生存期以及毒副反应。结果:总有效率治疗组为82.1%,对照组为53.6%,两组比较有显著性差异(P<0.05);治疗组0.5,1,1.5年生存率为85.7%,57.1%,35.7%,分别高于对照组的60.7%,35.7%,10.7%。治疗组发热较对照组有显著性差异(P<0.05)。结论:顺铂加斯奇康胸腔内注射治疗恶性胸腔积液,是一种有效、低毒、可耐受的方法。Objective:To evaluate the efficacy of Cisplati ne and Siqikang(BCG polysaccharide and nucleic acid)by injection through thoracic tube intubation on treatme nt malignant pleural effusion.Methods:56cases with malignant pleural effu sion,after drainage,Cisplatine40mg /m 2 and Siqikang 6mg were injected into p leural cavity in therapy group,and Cisplatine 40mg /m 2 only in control group.The treatment was repeated after a week,no more than three times efficacy,survival rate and toxicities were ev aluated.Results:The response rate was 82.1%in therapy group and 53.6%i n control group.There was sighificant difference in two groups(P<0.05).The half -year,one -year,one and half -year survival rates were 85.7%,57.1%,35.7%in therapy group and 60.7%,35.7%,10.7%in control group,respectively.Conclusion:The treatment of Cisplatine combined Siqikang through thoracic tube is r egarded as effective,less toxicities and well tolerated method for malignant pleu ral effusion.

关 键 词：顺铂 斯奇康 肺癌 恶性胸腔积液 胸腔内给药 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]